Comparing the Efficacy of Local Anesthetics in Mohs Surgery
Status:
Recruiting
Trial end date:
2021-06-14
Target enrollment:
Participant gender:
Summary
Mohs surgery is a very effective option in removing non-melanoma skin cancers, as the tissue
being removed is analyzed the same day. If there are remnants of cancer cells in the tissue
removed, the Mohs surgeon will go back and remove further tissue and repair the surgical
wound all within the same day.
Unfortunately, postoperative pain is quite prevalent among patients requiring Mohs
procedures, as up to 52% require an additional oral pain medication. Lidocaine is the most
commonly used anesthetic used in Mohs given its rapid onset of action. However, the duration
of lidocaine's effect is much shorter than bupivacaine, which may translate into increased
postoperative pain.
To date, there are no specific studies comparing bupivacaine alone, lidocaine alone or both
in conjunction in Mohs procedures.
The investigators predict bupivacaine alone and bupivacaine used in conjunction with
lidocaine are more effective in managing pain during Mohs surgery than lidocaine alone.
To test our hypothesis, the investigators plan to have 105 patients receive either lidocaine
alone, bupivacaine alone, or lidocaine and bupivacaine in conjunction during their Mohs
procedure. Pain will be evaluated at various time points throughout the surgery.
Phase:
N/A
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Benefactor Life Members' Research Grant Benefactor Life Members’ Research Grant Richard J. MacKay Endowment Fund The Ottawa Hospital Division of Dermatology
Treatments:
Anesthetics Anesthetics, Local Bupivacaine Lidocaine